| Editor’s Note: Vote now in #FierceMadness: The Best Biotech Name Tournament. The Final Four is open for voting! |
Today’s Big NewsApr 5, 2024 |
| By Max Bayer Sanofi is laying off staff around the globe following a 'full pipeline reprioritization,' according to an email from R&D chief Houman Ashrafian to staff. The communication, obtained by Fierce Biotech, refer to a large-scale restructuring to afford late-stage drug development. |
|
|
|
By James Waldron Contineum Therapeutics has lowered its IPO expectations as the Johnson & Johnson-partnered biotech prepares to make the jump to the public markets this morning. |
By Gabrielle Masson,Max Bayer From one Swiss CDMO to another. That’s the course for Wolfgang Wienand, who plans to jump from his role as Siegfried’s CEO over to Lonza. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
By Ayla Ellison This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged. |
By Conor Hale In a world first, a man with end-stage renal disease is now enjoying "one of the cleanest bills of health" in a long time, following a xenotransplant procedure at Massachusetts General Hospital. |
By Angus Liu AstraZeneca's Imfinzi has delivered positive clinical data in another type of lung cancer, building on the immunotherapy’s existing FDA clearance in stage 3 non-small cell lung cancer and extensive-stage small cell lung cancer. |
By Heather Landi In a major corporate shift, Jason Gorevic has stepped down as CEO of virtual care giant Teladoc after leading the company for 15 years. |
By Angus Liu Eisai and Biogen's subcutaneous Leqembi faces a regulatory delay. Johnson & Johnson and Legend Biotech have expanded their contract manufacturing deal with Novartis around Carvykti. A Chinese drugmaker is seeking local approval of a biosimilar version of Novo Nordisk's Ozempic. And more. |
Fierce podcastsDon’t miss an episode |
| This week on “The Top Line,” join Editor-in-Chief of Fierce Life Sciences and Healthcare Ayla Ellison as she sits down with Kumar Madassery, M.D., Director of Peripheral Vascular Intervention & CLI Program at Rush University Medical Center, to explore peripheral arterial disease—a serious health issue that is often overlooked and undermanaged. |
|
|---|
|
|
|
Available On-Demand Navigating the complexities of the rapidly evolving landscape of cell therapy manufacturing poses significant challenges. Access this discussion on-demand to learn more about the top challenges cell therapy developers are facing. We explore the need for closed, automated, and flexible manufacturing workflows that are designed to de-risk the process for clinical and commercial success. View now.
|
|
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
